This compound is a cytotoxic agent designed for use in antibody-drug conjugates, featuring a complex macrocyclic structure with multiple functional groups including amides, ethers, and a halogen atom. It is primarily employed as a pharmaceutical raw material in the manufacturing of targeted cancer therapeutics.
نطاق المحتوى: تتعلق المعلومات الواردة في هذه الصفحة بتحديد المواد الكيميائية وبسياقات التوريد الصناعي والبحث والإنتاج. وهي لا تشكّل ادعاءً علاجياً أو نصيحة طبية أو إرشادات لاستخدام الأدوية.
هل تشتري أو تورد هذا المركب؟
أضف مخزونك أو أنشر طلب شراء
CAS 1375089-56-7
Mertansine
antibody-drug conjugate payload
Maytansinoid DM3
antibody-drug conjugate payload
[(1S,2R,3S,5S,6S,16Z,18Z,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] (2S)-2-[6-[[[(2S)-2-[[(2R)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]propanoyl]amino]propanoyl]amino]propanoyl]amino]methylsulfanyl]hexanoyl-methylamino]propanoate
antibody-drug conjugate linker payload
Ravtansine
tubulin-binding maytansinoid anticancer agent
Bpc 157
investigational therapeutic peptide
(+)-2'-Deoxy-3'-thia-5-fluorocytidine
active pharmaceutical ingredient
Dioxopromethazine
active pharmaceutical ingredient
Gemigliptin tartrate sesquihydrate
active pharmaceutical ingredient
[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] (2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoyl-methylamino]propanoate
UGBPANNIQRLRII-RJPAQOSPSA-N
C[C@@H]1[C@@H]2C[C@]([C@@H](/C=C/C=C(/CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)C[C@@H]([C@]4([C@H]1O4)C)OC(=O)[C@H](C)N(C)C(=O)CCCCCN5C(=O)C=CC5=O)C)\C)OC)(NC(=O)O2)O